Olema Pharmaceuticals Inc (OLMA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $662.30M
Last updated: Nov 17, 2026 at 4:15 PM ET
Olema Pharmaceuticals Inc (OLMA) Statistics
Olema Pharmaceuticals (OLMA) has a market cap of $662.30M and an enterprise value of $617.78M. Revenue fell 100.00% over the last 12 months from the 12 months before. Its share count is up 17.92% from a year earlier.
Total Valuation
Enterprise value is 6.72% below the market cap, as cash exceeds debt.
| Market Cap | $662.30M |
|---|---|
| Enterprise Value | $617.78M |
| Latest price (Nov 17, 2026) | $7.22 |
Key Dates
The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 15, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 14.05% over 52 weeks and trades 10.20% below its 50-day average.
| Beta (1Y) | 1.43 |
|---|---|
| 52-Week Change | -14.05% |
| 1-Month Change | +1.55% |
| 3-Month Change | -36.16% |
| 6-Month Change | -44.89% |
| 5-Year Change | -74.07% |
| Total Return (1Y) | -14.05% |
| Total Return (3Y CAGR) | -23.15% |
| Total Return (5Y CAGR) | -21.96% |
| Return vs SPY (1Y) | -75.71% |
| Max Drawdown (1Y) | -82.11% |
| Max Drawdown (3Y) | -82.11% |
| Sharpe Ratio (1Y) | -1.42 |
| Correlation with SPY (1Y) | 0.27 |
| 50-Day Average | $8.04 |
| 200-Day Average | $12.90 |
| 52-Week Range | $6.24 to $36.26 |
| RSI (14 Days) | 46.1 |
| Average Volume (20 Days) | 1.48M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.12x current liabilities, and total debt is 0.01x shareholder equity.
| Current Ratio | 6.12x |
|---|---|
| Quick Ratio | 6.12x |
| Debt / Equity | 0.01x |
Returns and Efficiency
Return on invested capital is -53.81% over the last 12 months, against a 5-year average of -29.31%.
| Return on Equity (ROE) | -63.97% |
|---|---|
| Return on Assets (ROA) | -53.49% |
| Return on Invested Capital (ROIC) | -53.81% |
| ROE (5Y Average) | -36.34% |
| ROA (5Y Average) | -33.34% |
| ROIC (5Y Average) | -29.31% |
Scores
OLMA has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$187.00K |
| Operating Income | -$252.77M |
| Pretax Income | -$235.95M |
| Net Income | -$235.95M |
| Reported EPS (TTM) | -$2.36 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 83.62% of the $441.07M in total assets.
| Cash and Equivalents | $47.52M |
|---|---|
| Total Debt | $3.00M |
| Net Cash | $44.52M |
| Net Cash Per Share | $0.44 |
| Working Capital | $354.19M |
| Shareholder Equity | $368.84M |
| Book Value Per Share | $3.65 |
| Total Assets | $441.07M |
| Total Liabilities | $72.23M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$177.32M |
|---|---|
| FCF Per Share | -$2.04 |
| Depreciation and Amortization | $502.00K |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | +6.34% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +6.34% |
Dividends and Yields
OLMA does not pay a dividend.
| Buyback Yield | -4.98% |
|---|---|
| Shareholder Yield | -4.98% |
Peer Position
Against 7 similar companies, OLMA has the 7th highest ROIC.
ROICPeer median -14.91%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -82.85%
| ROIC | -53.81% vs -14.91% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -100.00% vs -82.85% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About OLMA
What is OLMA's market cap?
Olema Pharmaceuticals has a market cap of $662.30M. Its enterprise value, which adds debt and subtracts cash, is $617.78M.
How many shares of OLMA are outstanding?
Olema Pharmaceuticals has 101.09M shares outstanding. The count is up 17.92% from a year earlier.
Does OLMA pay a dividend?
No. Olema Pharmaceuticals does not pay a dividend.
How much debt does OLMA have?
Olema Pharmaceuticals has $3.00M of total debt and $47.52M of cash and equivalents, a net cash position of $44.52M.
OLMA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors